1. A cell culture comprising: (a) a culture medium containing one or more predetermined growth factors effective for inducing multipotent central nervous system (CNS) neural stem cell proliferation; and (b) suspended in the culture medium, human multipotent CNS neural stem cells wherein (i) the cells are grown in culture medium containing one or more predetermined growth factors effective for inducing multipotent CNS neural stem cell proliferation; (ii) the population comprises cells which stain positive for nestin; (iii) in the presence of differentiation-inducing conditions, the cells produce progeny cells that differentiate into neurons, astrocytes, or oligodendrocytes; and (iv) the cells have a doubling rate faster than 30 days.
Stem Cells Inc. touts in its offering prospectus that they are outside the stem cell controversy because their line of stem cells is not directly derived from embryos. Stem Cells Inc.'s process reproducibly grows large numbers of stem cells so that they can be "banked" and used for therapeutic treatments at a later date.
Thus, the patent appears to only cover a cell culture capable of enhancing the growth or reproduction of multipotent stem cells and not stem cells in general.